Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study

Morag Griffin, Richard J. Kelly, Mathilde Gavillet, Petra Muus, Britta Hoechsmann, W. Jason Cummings, John Efthimiou, William Pullman, Hubert Schrezenmeier, Jens Panse

Blood (2024) 144 (Supplement 1): 4072.

https://doi.org/10.1182/blood-2024-205866

Published: 2024

Journal Articles

Ravulizumab in Pregnant Women with Paroxysmal Nocturnal Hemoglobinuria (PNH) - Favourable Experience from a Retrospective Case Series

Britta Hoechsmann, Wilhelm Leopold, Ariane Schneider, Sixten Koerper, Ursula Kalhammer, Hubert Schrezenmeier

Blood (2024) 144 (Supplement 1): 5251.

https://doi.org/10.1182/blood-2024-209857

Published: 2024

Journal Articles

Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders - Results from the Aachen Telomeropathy Registry

Blood (2021) 138 (Supplement 1): 1130.

https://doi.org/10.1182/blood-2021-153630

Published: 2021

Journal Articles

Upfront Alternative Donor Transplant Versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack Fully HLA Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies. on Behalf of the Severe Aplastic Anemia Working Party of European Group for Blood and Marrow Transplantation (SAAWP of EBMT)

Hind Alotaibi, MBBS, Mahmoud Aljurf, Regis Peffault De Latour, MD PhD, Shahid Iqbal, Andrea Bacigalupo, Judith Marsh, Hubert Schrezenmeier, Eliane Gluckman, Mansour Alfayez, Britta Hoechsmann, Constantijn Halkes, Josu de la Fuente, Nawal AlShehry, Simone Cesaro, Jakob Passweg, Carlo Dufour, Antonio Risitano, John F. DiPersio, MD PhD, Ibraheem Motabi

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-140846

Published: 2020

Journal Articles

Effect of Pegcetacoplan on Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Pegasus Phase 3 Trial Comparing Pegcetacoplan to Eculizumab

Alexander Röth, MD, Britta Hoechsmann, Morag Griffin, MBChB, FRCPath, Carlos M. de Castro, MD, Jeffrey Szer, MBBS, Kensuke Usuki, MD PhD, Juliette Soret, MD, Mohamed Hamdani, MS, Temitayo Ajayi, Sujata P. Sarda, PhD, Jens Panse, MD

Blood (2020) 136 (Supplement 1): 10–12.

https://doi.org/10.1182/blood-2020-134581

Published: 2020

Journal Articles

Risk Factors for Thrombotic Events in Patients with PNH: A Nested Case-Control Study in the International PNH Registry

Britta Hoechsmann, Regis Peffault De Latour, MD PhD, Anita Hill, Alexander Röth, MD, Timothy Devos, MD, Christopher Patriquin, Wen-Chien Chou, MD PhD, Deepak Jain, Ke Zu, Jong Wook Lee, MD, PhD

Blood (2020) 136 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2020-136767

Published: 2020

Journal Articles

Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

Peter Hillmen, MBChB, PhD, Jeffrey Szer, MBBS, Ilene C. Weitz, Alexander Röth, MD, Britta Hoechsmann, Jens Panse, MD, Kensuke Usuki, MD PhD, Morag Griffin, MBChB, FRCPath, Jean-Jacques Kiladjian, MD PhD, Carlos M. de Castro, MD, Hisakazu Nishimori, MD PhD, Lisa Tan, Mohamed Hamdani, Pascal Deschatelets, PhD, Cedric Francois, MD PhD, Federico Grossi, MD, Antonio Risitano, Regis Peffault De Latour, MD PhD

Blood (2020) 136 (Supplement 1): 35–37.

https://doi.org/10.1182/blood-2020-142174

Published: 2020

Journal Articles

Efficacy of Eculizumab in Pediatric Patients with Paroxysmal Nocturnal Hemoglobinuria in the International PNH Registry

Álvaro Urbano-Ispizua, MD PhD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Marije Bartels, MD PhD, Christopher J. Patriquin, MD MSc, FRCPC, Britta Hoechsmann, MD, Alexey A. Maschan, MD, Amanda Wilson, PhD, Philippe Gustovic, MD, Hubert Schrezenmeier, MD

Blood (2018) 132 (Supplement 1): 3614.

https://doi.org/10.1182/blood-2018-99-111306

Published: 2018

Journal Articles

Long-Term Follow-up of the Randomized Controlled Study in Patients with Newly Diagnosed Severe Aplastic Anemia Treated with ATG, Cyclosporine, with or without G-CSF: On Behalf of the SAA Working Party of the EBMT

André Tichelli, MD, Regis Peffault De Latour, Jakob R. Passweg, MD PhD, Cora Knol, Gérard Socié, MDPhD, Judith Marsh, Britta Hoechsmann, MD, Hubert Schrezenmeier, MD, Andrea Bacigalupo, MD, Sujith Samarasinghe, Alicia Rovo, MD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Dirk-Jan Eikema, Paul Bosman, Peter Bader, MD PhD, Antonio M. Risitano, MD PhD, Carlo Dufour, MD

Blood (2018) 132 (Supplement 1): 1307.

https://doi.org/10.1182/blood-2018-99-111811

Published: 2018

Journal Articles

Use of Blood Transfusions In Paroxysmal Nocturnal Hemoglobinuria Patients with and without Aplastic Anemia Enrolled In the Global PNH Registry

Hubert Schrezenmeier, Robert A Brodsky, MD, Petra Muus, MD, PhD, Monica Bessler, MD, PhD, Jeffrey Szer, MBBS, FRACP, Jaroslaw P Maciejewski, MD, PhD, FACP, Gérard Socié, Alvaro Urbano-Ispizua, MD, Yuzuru Kanakura, MD, PhD, Britta Hoechsmann, Wendell F Rosse, MD, Gus Khursigara, PhD, Anders Karnell, MD, PhD, Camille L Bedrosian, MD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 2241.

https://doi.org/10.1182/blood.V116.21.2241.2241

Published: 2010

NARROW

Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study

Ravulizumab in Pregnant Women with Paroxysmal Nocturnal Hemoglobinuria (PNH) - Favourable Experience from a Retrospective Case Series

Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders - Results from the Aachen Telomeropathy Registry

Effect of Pegcetacoplan on Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Pegasus Phase 3 Trial Comparing Pegcetacoplan to Eculizumab

Risk Factors for Thrombotic Events in Patients with PNH: A Nested Case-Control Study in the International PNH Registry

Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

Efficacy of Eculizumab in Pediatric Patients with Paroxysmal Nocturnal Hemoglobinuria in the International PNH Registry

Long-Term Follow-up of the Randomized Controlled Study in Patients with Newly Diagnosed Severe Aplastic Anemia Treated with ATG, Cyclosporine, with or without G-CSF: On Behalf of the SAA Working Party of the EBMT

Use of Blood Transfusions In Paroxysmal Nocturnal Hemoglobinuria Patients with and without Aplastic Anemia Enrolled In the Global PNH Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only